达布拉芬尼
威罗菲尼
V600E型
肿瘤科
突变
脑转移
神经母细胞瘤RAS病毒癌基因同源物
转移性黑色素瘤
无容量
内科学
作者
Zhiyuan Xu,Cheng-Chia Lee,Arjun Ramesh,Adam C. Mueller,David Schlesinger,Or Cohen-Inbar,Han-Hsun Shih,Jason P. Sheehan
标识
DOI:10.3171/2016.2.jns1633
摘要
OBJECTIVE Recent advancements in molecular biology have identified the BRAF mutation as a common mutation in melanoma. The wide use of BRAF kinase inhibitor (BRAFi) in patients with metastatic melanoma has been established. The objective of this study was to examine the impact of BRAF mutation status and use of BRAFi in conjunction with stereotactic radiosurgery (SRS). METHODS This was a single-center retrospective study. Patient's charts and electronic records were reviewed for date of diagnosis of primary malignancy, BRAF mutation status, chemotherapies used, date of the diagnosis of CNS metastases, date of SRS, survival, local tumor control after SRS, and adverse events. Patients were divided into 3 groups: Group A, those with mutant BRAF without BRAFi treatment (13 patients); Group B, those with mutant BRAF with BRAFi treatment (17 patients); and Group C, those with wild-type BRAF (35 patients). Within a cohort of 65 patients with the known BRAF mutation status and treated with SRS between 2010 and 20...
科研通智能强力驱动
Strongly Powered by AbleSci AI